Safety of ixazomib for the treatment of multiple myeloma.

about

Safety of ixazomib for the treatment of multiple myeloma.

Item

http://www.wikidata.org/entity/Q39404809

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Safety of ixazomib for the treatment of multiple myeloma.

@en

Safety of ixazomib for the treatment of multiple myeloma.

@nl

type

Item

label

Safety of ixazomib for the treatment of multiple myeloma.

@en

Safety of ixazomib for the treatment of multiple myeloma.

@nl

prefLabel

Safety of ixazomib for the treatment of multiple myeloma.

@en

Safety of ixazomib for the treatment of multiple myeloma.

@nl

P1476

Safety of ixazomib for the treatment of multiple myeloma.

@en

P2093

Antoine Bonnet

http://www.w3.org/2001/XMLSchema#string

Philippe Moreau

http://www.w3.org/2001/XMLSchema#string

P2860

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design

Cancer statistics, 2015

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

P304

973-980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2017.1344212

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28661711

http://www.w3.org/2001/XMLSchema#string